Related Experiment Video
Updated: Nov 10, 2025
07:13
Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
Published on: April 12, 2021
4.6K
Medication non-adherence among liver transplant recipients
Lauren S Jones1,2, Marina Serper1
1Division of Gastroenterology and Hepatology, University of Pennsylvania Perelman School of Medicine.
Current Hepatology Reports
|April 5, 2021
Summary
Medication non-adherence is common in liver transplant recipients, linked to various factors and poor outcomes. Further research is needed to develop effective interventions for improving adherence in this population.
Area of Science:
- Transplant medicine
- Pharmacology
- Patient adherence research
Background:
- Medication non-adherence (NA) poses significant risks to liver transplant (LT) recipients.
- Understanding NA's prevalence, risk factors, and consequences is crucial for patient outcomes.
Purpose of the Study:
- To review current evidence on NA in LT recipients.
- To identify factors associated with NA and its impact.
- To highlight gaps in research regarding NA predictors and interventions.
Main Methods:
- Literature review of recent evidence on medication non-adherence in liver transplant recipients.
- Analysis of factors contributing to NA, including socio-demographic, medication-related, social support, and health literacy.
- Evaluation of methods for measuring NA, such as patient-reported assessments, drug levels, and electronic monitoring.
Main Results:
- NA in LT is associated with socio-demographic factors, medication characteristics, low social support, and poor health literacy.
- Patient-reported adherence is a common measurement tool; immunosuppression drug levels and electronic monitoring are also utilized.
- Simplifying immunosuppression regimens (e.g., once-daily dosing) improves adherence and is safe and effective.
Conclusions:
- Medication non-adherence is a prevalent, complex issue in LT recipients with serious adverse outcomes.
- Limited prospective studies and interventions exist for reducing NA in LT.
- Further research is essential to address NA and improve long-term outcomes in liver transplant patients.
Related Concept Videos
01:16Kidney Transplant III: Nursing Management
133
Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
133
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
85
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
85
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
54
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
54
01:28Kidney Transplant I: Introduction
128
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
128
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
71
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
71
01:26Kidney Transplant II: Surgical Procedure
134
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
134